Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
By S. Mudaliar, R. Henry, A. Sanyal, L. Morrow, Hanns-Ulrich Marschall, M. Kipnes, L. Adorini, Cathi Sciacca, P. Clopton, E. Castelloe and 3 more. Gastroenterology, 2013
875 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/ee63ef49fb957740321a730335c4e24b241a9a64
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Epidemiology
- V. Samuel
- Gerald I. Shulman
- Tiangang Li
- J. Y. Chiang
- F. Bäckhed
- David S. Wishart
- Haiming Cao
- D. Clegg
In Oncology
- Tiangang Li
- Hanns-Ulrich Marschall
- J. Y. Chiang
- F. Bäckhed
- A. Wahlström
- Sama I Sayin
- David S. Wishart
Citations in the corpus
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. (2015, positive): “A phase 2a proof-of-concept trial confirmed that obeticholic acid exerts a hepatoprotective effect on fibrosis (39).”
- Bile Acid Signaling in Metabolic Disease and Drug Therapy (2014, background): “A phase II clinical trial of OCA for NAFLD and T2DM patients showed improved insulin sensitivity, reduced g-glutamyl-transpeptidase levels (a marker of NASH), and weight loss (Mudaliar et al., 2013).”
- Non-Alcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases (2017, positive): “Obeticholic acid has been shown to increase serum FGF19 concentrations in humans (Mudaliar et al., 2013).”
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. (2019, background): “Furthermore, the combination of exenatide and insulin glargine was shown to decrease LFTs and reverse hepatic steatosis (evaluated by ultrasonography) more effectively than the intensive insulin therapy (insulin glargine and insulin aspart) in another 4-month RCT with obese with T2DM and NAFLD [173]”
- Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. (2016, positive): “Treatment with OCA for 6 weeks in patients with NAFLD and T2DMdose-dependently improved insulin sensitivity, estimated by euglycemic clamp, and reduced body weight, compared with placebo (Mudaliar et al., 2013).”